Auspex Pharma nails down $25M in D round; Merck gets standard FDA review for sleep drug;

Conversations on Twitter :

 @FierceBiotech: After cashing in on life-saving boast, biotech stayed mum on patient death. Story | Follow @FierceBiotech

 @JohnCFierce: Catalyst $CPRX cocaine addiction drug flops in phase IIb, shares down 65%--a penny stock now. More | Follow @JohnCFierce

 @RyanMFierce: GNS Healthcare, Mt. Sinai and Farber want to drop a Big Data bomb on cancer with a computer model of mult. myeloma. Release | Follow @RyanMFierce

> Auspex Pharmaceuticals in La Jolla, CA, which plans to enter late-stage development with a lead compound for Huntington's disease, has reeled in $25 million from a Series D round of financing with lead backer Panorama Capital joined by Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund. Release

> The Belgian biotech Galapagos revealed evidence of safety and efficacy from a Phase IIa study of its JAK1 inhibitor GLPG0634 in patients with rheumatoid arthritis. News

> The FDA has granted Merck ($MRK) a standard review for its experimental sleep drug, suvorexant, and accepted the company's New Drug Application. Release

> Nimbus Discovery and Proteros Biostructures have joined forces in a partnership for drug discovery. Item

Pharma News

@FiercePharma: Will Merck's Oxytrol benefit from new FDA interest in OTC access? More | Follow @FiercePharma

> GSK, XenoPort part ways after Horizant disappointment. Article

> Sun joins dermatology rush with $230M Dusa buyout. News

> Long-term study reinforces safety record of blockbuster Pradaxa. Story

Medical Device News

 @FierceMedDev: Theragenics faced slumping revenue in Q3. The device maker blames hc reform, the device tax and economic uncertainty. More | Follow @FierceMedDev

 @MarkHFierce: OraSure's new HIV rapid Dx test helped reduce losses in Q3. News | Follow @MarkHFierce

 @DamianFierce: Boston Sci is now a hypertension player, spending $425M on Vessix, a Fierce 15 winner. More | Follow @DamianFierce

> GenMark's revenue soars as loss narrows. News

> Bausch + Lomb snatches up ophthalmology laser startup. Item

Vaccine News

 @AlisonBFierce: The percentage of drug-resistant malaria cases is on the rise in Southeast Asia, a cause for concern among experts. News | Follow @AlisonBFierce

> GSK withdraws infant vaccine in Canada. Article

> BiondVax, MonoSol Rx develop oral universal flu vaccine. News

> Scripps researchers develop methamphetamine vaccine. Story

> PsiOxus lands $2.7M for ovarian cancer vaccine trial. Item

Pharma Manufacturing News

> African raids seize 82M doses of counterfeits. Report

> Another online seller of fake Viagra heads for jail. Story

> Hospira slowly ramps up production. Article

> GlaxoSmithKline pulls vaccines after bacteria found in plant. News

And Finally… Signs of baldness are markers for heart disease, researchers report. Article

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.